Group members

Wang S, Santacana-Font G, Kedra D, Gilfillan S, Tena-Chaves D, Bergholtz H, Engebraaten O, Lingjaerde OC, Gutiérrez-Fernández J, Norum JH, Sørlie T, López-Aviles S, Hurtado A (2025)
The harmonized activities of HER2-HER3 heterodimer and deacetylated FOXA1 evade hormone response by regulating FOXA1 chromatin binding
Nucleic Acids Res, 53 (20)
DOI 10.1093/nar/gkaf1086, PubMed 41224124

Demeestere I, Niman SM, Partridge AH, Diego DS, Kammler R, Ruggeri M, Colleoni M, Shimizu C, Saura C, Gelmon KA, Saetersdal AB, Kroep JR, Mailliez A, Amant F, Ruız-Borrego M, Lee JE, Kataoka A, Walshe JM, Takei J, Borstnar S, Borges VF, Saunders C, Susnjar S, Bjelic-Radisic V, Cardoso F et al. (2025)
Corrigendum to "Hormonal factors predictive of fertility in patients with breast cancer interrupting adjuvant endocrine therapy to attempt pregnancy in POSITIVE trial" [The Breast 83 (2025) 104547]
Breast, 84, 104570 (in press)
DOI 10.1016/j.breast.2025.104570, PubMed 40987054

Vandraas KF, Hjorth S, Trewin-Nybråten CB, Ursin G, Botteri E, Andreassen BK, Reinertsen KV, Blix ES, Naume B, Støer NC (2025)
Anti-Her2 therapy patterns in metastatic breast cancer-Real-world data suggest undertreatment
Int J Cancer (in press)
DOI 10.1002/ijc.70120, PubMed 40892038